Incyte (INCY) Other financing activities (2011 - 2026)
Incyte's (INCY) quarterly Other financing activities came in at $75.1 million in Q2 2026, up 404.89% YoY from $14.9 million in Q2 2025, and down 23.26% on a QoQ basis from $97.9 million in Q1 2026.
Incyte (INCY) Other financing activities (2011 - 2026) Analysis & Trends
Incyte (INCY) has 16 years of Other financing activities data on file, last reported at $75.1 million in Q2 2026.
- Quarterly Other financing activities rose 404.89% year-over-year to $75.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $376.7 million (up 618.04% YoY) and the FY2025 annual result came in at $221.8 million, up 349.81% from the prior year.
- Other financing activities fell to $75.1 million in Q2 2026, from $97.9 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $160.2 million in Q4 2025 to a low of -$48000.0 in Q3 2023.
- A 5-year average of $30.1 million and a median of $14.7 million in 2024 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2023 — Other financing activities sank 100.91% — and 2025, when it soared 3287.68%.
- Tracing INCY's Other financing activities over 5 years: stood at $18.1 million in 2022, then plunged by 58.53% to $7.5 million in 2023, then jumped by 339.79% to $33.1 million in 2024, then jumped by 384.62% to $160.2 million in 2025, then sank by 53.09% to $75.1 million in 2026.
- The last three Other financing activities figures came in at $75.1 million (Q2 2026), $97.9 million (Q1 2026), and $160.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.15 Mn |
| Jun 30, 2026 | 75.15 Mn |
| Mar 31, 2026 | 97.93 Mn |
| Mar 31, 2026 | 97.93 Mn |
| Dec 31, 2025 | 160.21 Mn |
| Dec 31, 2025 | 160.21 Mn |
| Sep 30, 2025 | 43.43 Mn |
| Sep 30, 2025 | 43.43 Mn |
| Jun 30, 2025 | 14.88 Mn |
| Jun 30, 2025 | 14.88 Mn |
| Mar 31, 2025 | 3.24 Mn |
| Mar 31, 2025 | 3.24 Mn |
| Dec 31, 2024 | 33.06 Mn |
| Dec 31, 2024 | 33.06 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 14.48 Mn |
| Jun 30, 2024 | 14.48 Mn |
| Mar 31, 2024 | 477,000.00 |
| Mar 31, 2024 | 477,000.00 |